Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study

Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study

ABSTRACT The combination of Elexacaftor/Tezacaftor/Ivacaftor (ETI) has resulted in a significant improvement in lung function and global clinical parameters, which have not been previously achieved with other CFTR modulators. However, there is a paucity of evidence in the literature on the long‐term...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicola Perrotta, Luigi Angelo Fiorito, Gianfranco Casini, Rossella Gentile, Roberta Vescovo, Alfonso Piciocchi, Roberta Lobello, Carlo Cappelli, Roberto Poscia, Giuseppe Cimino
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Pharmacology Research & Perspectives
Subjects:
CFTR
cystic fibrosis
effectiveness
Elexacaftor‐Tezacaftor‐Ivacaftor
safety
Online Access:https://doi.org/10.1002/prp2.70083
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/prp2.70083

Similar Items